Bristol-Myers Squibb

Recent news

• RBC Capital Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Maintains Target Price $64
  Market Newswire · 9/15
• Piper Sandler Maintains Bristol-Myers Squibb(BMY.US) With Buy Rating, Raises Target Price to $82
  Market Newswire · 9/16
• Rating change
  Citi Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Maintains Target Price $70
  Market Newswire · 8/14
• Rating change
  William Blair Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating
  Market Newswire · 8/14
• UBS Maintains Bristol-Myers Squibb(BMY.US) With Buy Rating, Maintains Target Price $80
  Market Newswire · 8/20
• Rating change
  Barclays Maintains Bristol-Myers Squibb(BMY.US) With Buy Rating, Maintains Target Price $75
  Market Newswire · 8/12
• Bernstein Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating
  Market Newswire · 8/21
• Rating change
  J.P. Morgan Maintains Bristol-Myers Squibb(BMY.US) With Buy Rating, Maintains Target Price $73
  Market Newswire · 8/5
• HSBC Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Raises Target Price to $65
  Market Newswire · 9/10
• Rating change
  Citi Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Raises Target Price to $70
  Market Newswire · 8/3
• Rating change
  BofA Securities Maintains Bristol-Myers Squibb(BMY.US) With Buy Rating, Maintains Target Price $71
  Market Newswire · 8/3
• Rating change
  Argus Research Upgrades Bristol-Myers Squibb(BMY.US) to Buy Rating, Announces Target Price $75
  Market Newswire · 8/5

Headlines are aggregated automatically and are not independently verified or edited by our team.